If the MGMT promoter is methylated, it will cause a loss in MGMT expression, resulting in a decrease in DNA repair and making gliomas more sensitive to chemotherapy drugs such as TMZ [39], and, therefore, the MGMT promoter methylation status was considered as an independent predictor of prognosis in patients with gliomas [40]. This evidence concerns the gene MGMT and central nervous system cancer.